Drugs / tNIV Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT06291857 | Dec 2024 → Dec 2025 | COVID-19 | Novavax | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-10-16 | Novavax | Regulatory Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial novavax.com ↗
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on Novavax's Investigational New Drug (IND) application for its COVID-19-Influenza Combination (CIC) and stand-alone influenza vaccine candidates. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-10-16 | Novavax | Update on Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Phase 3 Trial novavax.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tNIV Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06291857 ↗ |
| Modality | Vaccine | “tNIV Vaccine” NCT06291857 ↗ |
| Route | Intramuscular | “single intramuscular (IM) injection on Day 0” NCT06291857 ↗ |